Founded in 2000, XDx, Inc. is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information.
XDx has one marketed product, AlloMap® Molecular Expression Testing, and other products under development. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored.